The University of Chicago Header Logo

Connection

Dejan Micic to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Dejan Micic has written about Treatment Outcome.
Dejan Micic
Connection Strength
0.390
Treatment Outcome
  1. Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis. Nutr Clin Pract. 2024 Jun; 39(3):634-640.
    View in: PubMed
    Score: 0.095
  2. Mediastinal granuloma: a rare cause of dysphagia. BMJ Case Rep. 2016 Jun 14; 2016.
    View in: PubMed
    Score: 0.056
  3. Factors associated with long-term clinical outcome in microscopic colitis. Ann Med. 2024 Dec; 56(1):2365989.
    View in: PubMed
    Score: 0.024
  4. Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes. Clin Gastroenterol Hepatol. 2021 11; 19(11):2444-2446.e2.
    View in: PubMed
    Score: 0.019
  5. Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis. 2020 Nov; 35(11):2113-2116.
    View in: PubMed
    Score: 0.019
  6. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
    View in: PubMed
    Score: 0.017
  7. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019 02; 17(3):486-493.
    View in: PubMed
    Score: 0.016
  8. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018 Mar; 47(6):753-762.
    View in: PubMed
    Score: 0.016
  9. Meta-Analysis of the Risk of Immune-Related Adverse Events With Anticytotoxic T-Lymphocyte-Associated Antigen 4 and Antiprogrammed Death 1 Therapies. Clin Pharmacol Ther. 2018 02; 103(2):318-331.
    View in: PubMed
    Score: 0.015
  10. Autoimmune gastrointestinal dysmotility due to small cell lung cancer. BMJ Case Rep. 2017 Aug 11; 2017.
    View in: PubMed
    Score: 0.015
  11. Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysis. J Gastroenterol Hepatol. 2017 Jun; 32(6):1143-1151.
    View in: PubMed
    Score: 0.015
  12. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-a agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017 04; 45(8):1043-1057.
    View in: PubMed
    Score: 0.015
  13. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-a agents in rheumatic diseases; A systematic review and meta-analysis. J Autoimmun. 2017 May; 79:4-16.
    View in: PubMed
    Score: 0.015
  14. Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-a use in females with immune mediated diseases; a systematic review and meta-analysis. J Autoimmun. 2017 01; 76:38-52.
    View in: PubMed
    Score: 0.014
  15. Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. J Crohns Colitis. 2016 Dec; 10(12):1385-1394.
    View in: PubMed
    Score: 0.014
  16. The benefit of paracentesis on hospitalized adults with cirrhosis and ascites. J Gastroenterol Hepatol. 2016 May; 31(5):1025-30.
    View in: PubMed
    Score: 0.014
  17. Patchy colitis and interstitial lung disease. Gastroenterology. 2015 Jan; 148(1):26-7.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.